Roche is developing CT-868, a dual GLP‑1/GIP receptor agonist, in a mid‑stage (Phase 2) trial for overweight or obese adults with type 1 diabetes (T1D).\nInterim data and slide‑deck summaries indicate that CT‑868 improved glycemic control in this group, with a substantial reduction in HbA1c compared with placebo and a high proportion of participants reaching an HbA1c ≤6.5%.\nThe trial tests CT‑868 as an adjunct to standard insulin therapy and is expected to complete data read‑out in 2025; Roche has flagged first‑in‑class potential for an incretin‑based add‑on in T1D.\nCT‑868 is also being studied for obesity and is distinct from Roche’s other incretin candidates (CT‑388, CT‑996, petrelintide) that are focused on obesity and type 2 diabetes.
Sources:
Roche enters into an exclusive collaboration & licensing agreement ...
[Ad hoc announcement pursuant to Art. 53 LR ... - Roche
Roche to present new data advancing its obesity portfolio at the ...
A Study of CT-868 in Type 1 Diabetes Mellitus - For Patients - Roche
Roche: CT-388 Dual GLP1-GIP Receptor Agonist Clinically ...
Roche reports positive data from Phase I obesity treatment ...
Roche outlines commercial manufacturing strategy for GLP ...
Roche, trailing in obesity, showcases new data for GLP-1 shot
[Ad hoc announcement pursuant to Art. 53 LR ... - Roche
Diabetes Drug to Start Late Stage Trial
Roche's 22% Weight Loss Benefit Seals GLP-1's Phase III Plans ...
Roche, Zealand tout the tolerability of their amylin obesity drug